Picture loading failed.

Anti-α4β7 therapeutic antibody (Pre-made Abrilumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Abrilumab (INN; development code AMG 181) is a monoclonal antibody designed for the treatment of inflammatory bowel disease, ulcerative colitis, and Crohn's disease.This drug was developed by MedImmune.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-005-1mg 1mg 3090
GMP-Bios-ab-005-10mg 10mg 21890
GMP-Bios-ab-005-100mg 100mg 148000
GMP-Bios-ab-005-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-α4β7 therapeutic antibody (Pre-made Abrilumab biosimilar,Whole mAb)
INN Name Abrilumab
Targetα4β7
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2014
Year Recommended2015
CompaniesAmgen;AstraZeneca
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedCrohn's disease;Ulcerative colitis
Development Techna